Live
FierceBiotechChutes & Ladders—Bayer radiology head takes top U.S. pharma spotEndpoints NewsOpenLoop Health has acquired nutrition startup Season HealthFierceBiotechPremier Radiology acquires teleradiology specialist GLOBISFierceBiotech‘Portfolio assessment’ prompts Ferring to terminate 2 fertility trialsFierceBiotechUK signs off on US pharma deal, ensuring tariff reprieve as Britain aims to reattract investmentsEndpoints NewsTrump signs order to put 100% pharma tariffs on drugs, countries without trade dealsScienceHow fast is the universe expanding? Cosmic ‘illusions’ may hold answerEndpoints NewsAspect Biosystems gets $79M from Canadian government for diabetes cell therapyLonza NewsFormulating Plant-Based and Organic Supplements: A Conversation with Lonza CHI - Nutritional OutlookEndpoints NewsDOJ weighs in favor of pharma on 340B disputeEndpoints NewsThe peptide fad lures health techIlluminaUPC refuses early knockout in Illumina–Element dispute - Life Sciences Intellectual Property Review
BioPharma Dive Apr 2, 2026

Immunovant eye drug flunks Phase 3 studies; Beam sickle cell data published in NEJM

Immunovant eye drug flunks Phase 3 studies; Beam sickle cell data published in NEJM

Original
Body unavailable. Use the original source.

Directory

59 All